Acinetobacter

被引:20
作者
Rahal, JJ
Urban, C
机构
[1] New York Hosp, Med Ctr Queens, Flushing, NY 11355 USA
[2] Cornell Univ, Sanford & Joan Weill Med Coll, New York, NY USA
关键词
Acinetobacter calcoaceticus-baumannii complex; multiresistance; infection control interventions;
D O I
10.1055/s-2000-9858
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Members of the genus Acinetobacter are oxidase negative, aerobic Gramnegative coccobacilli, which have evolved taxonomically from former strains of the Mima-Herrelia group. Their natural habitat is human skin and mucous membranes, water, soil, vegetation, and sewage. The most common multiresistant nosocomial pathogen among 19 genospecies is the A. calcoaceticus-baumannii complex (A, baumannii). This species is not a common component of normal human acinetobacter colonization, and its ecological origin remains unknown, Outbreaks of nosocomial acinetobacter infection are due to spread of one or a few clones among patients, personnel, and the inanimate hospital environment. Thus, strict implementation of infection control procedures is the major technique for prevention and suppression of such outbreaks. Surveillance cultures of personnel and the environment; molecular genotyping of isolates; cohorting of colonized or infected patients and staff; and topical application of polymyxin B to colonized wounds have been used to enhance standard infection control procedures. Antimicrobial resistance to beta lactam antibiotics in Acinetobacter is due primarily to a combination of chromosomal beta lactamase production and reduced outer membrane permeability, Carbapenem resistance is an increasing phenomenon and restriction of late-generation cephalosporin and carbapenem utilization should be considered in outbreak control. Effective therapy of multiresistant Acinetobacter infection may require a variety of potentially synergistic antibiotic combinations.
引用
收藏
页码:341 / 348
页数:8
相关论文
共 82 条
[1]   Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina [J].
Afzal-Shah, M ;
Villar, HE ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :127-131
[2]  
ALAMI SY, 1966, AM J MED SCI, V252, P537
[3]  
[Anonymous], 1998, 20 BAS NE ID SYST NO, P1
[4]   USE OF CEFOTAXIME FOR TREATMENT OF ACINETOBACTER INFECTIONS [J].
ANSTEY, NM .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (02) :374-374
[5]   COMMUNITY-ACQUIRED ACINETOBACTER PNEUMONIA IN THE NORTHERN TERRITORY OF AUSTRALIA [J].
ANSTEY, NM ;
CURRIE, BJ ;
WITHNALL, KM .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (01) :83-91
[6]  
Bergogne-Berezin E., 1996, CLIN MICROBIOL REV, V9, P148
[7]   Distribution of Acinetobacter species on skin of healthy humans [J].
Berlau J. ;
Aucken H. ;
Malnick H. ;
Pitt T. .
European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18 (3) :179-183
[8]   Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2 [J].
Brown, S ;
Bantar, C ;
Young, HK ;
Amyes, SGB .
LANCET, 1998, 351 (9097) :186-187
[9]  
BRUNBUISSON C, 1994, INFECT CONT HOSP EP, V15, P447
[10]   Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents [J].
Carmeli, Y ;
Troillet, N ;
Eliopoulos, GM ;
Samore, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1379-1382